American biotech Geneticure has received Patent No. 12,351,873 from the US Patent and Trademark Office (USPTO) for its genetic test to predict response in renal denervation, which is a minimally invasive procedure to treat hypertension.
The company developed the cheek-swab genetic screening test designed to detect those unlikely to respond to renal denervation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Geneticure noted that renal denervation has shown potential in lowering blood pressure by reducing renal nerve signalling through various techniques.
The patented method uses certain genetic markers in combination with a weighted algorithm to assess a patient’s responsiveness to renal denervation, allowing healthcare providers to tailor treatment plans.
With the addition of this patent to its intellectual property portfolio, the company is said to bolster its position in the pharmacogenomics and device response prediction sectors.
The company, which specialises in integrated computational genomic medicine, aims to eradicate the trial-and-error method of treating chronic conditions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBy incorporating genetic data with physiological insights, it offers physicians actionable solutions to enhance outcomes and the selection of the therapy.
Geneticure’s portfolio also includes genetic tests that predict responses to common hypertension medications.
Geneticure CEO Scott Snyder said: “Renal denervation has demonstrated the ability to reduce blood pressure in certain patients, with others experiencing no change or an increase in blood pressure post-denervation.
“Prior to Geneticure’s research, a reliable method of predicting the response had not yet emerged, and regardless of the denervation method, the changes in blood pressure have been variable across patient populations. Our technology has proven to identify the individuals most likely to respond, enabling more targeted use of this emerging therapy with increased prospects for adoption and payer coverage.”
